Professional
Added to YB: 2024-12-16
Pitch date: 2024-12-10
NVO [bullish]
Novo Nordisk A/S
-65.3%
current return
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 105.66
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
growth
Show full summary:
Pine Stone Asset Management Portfolio Holding: Novo Nordisk A/S
NVO: Insulin leader since 2009, disrupted industry with GLP-1 drugs (Ozempic/Wegovy) for diabetes & weight loss. Huge market, sticky customers. Strong organic growth, R&D focus. Eli Lilly main competitor. Trimmed position due to recent excitement, but still bullish on long-term prospects. Oral drug in development.
Read full article (5 min)